Polaris Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Polaris Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.16M	Sell	22,500 -3,300	-13%	-$168K	0.1%	74
2025 Q4	$1.28M	Hold	25,800	–	–	0.11%	73
2025 Q3	$1.23M	Sell	25,800 -17,300	-40%	-$697K	0.08%	73
2025 Q2	$1.36M	Hold	43,100	–	–	0.09%	76
2025 Q1	$1.41M	Sell	43,100 -3,900	-8%	-$138K	0.08%	71
2024 Q4	$1.7M	Buy	47,000 +4,500	+11%	+$158K	0.08%	68
2024 Q3	$1.33M	Hold	42,500	–	–	0.07%	79
2024 Q2	$1.14M	Hold	42,500	–	–	0.06%	75
2024 Q1	$1.45M	Hold	42,500	–	–	0.07%	63
2023 Q4	$1.23M	Hold	42,500	–	–	0.06%	74
2023 Q3	$1.17M	Hold	42,500	–	–	0.06%	72
2023 Q2	$1.28M	Hold	42,500	–	–	0.05%	73
2023 Q1	$1.54M	Hold	42,500	–	–	0.06%	66
2022 Q4	$1.52M	Buy	42,500 +9,600	+29%	+$334K	0.05%	63
2022 Q3	$1.11M	Hold	32,900	–	–	0.04%	74
2022 Q2	$951K	Hold	32,900	–	–	0.03%	75
2022 Q1	$1.06M	Hold	32,900	–	–	0.03%	74
2021 Q4	$959K	Hold	32,900	–	–	0.03%	86
2021 Q3	$877K	Hold	32,900	–	–	0.03%	89
2021 Q2	$1.01M	Buy	+32,900	New	+$1.01M	0.03%	84

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Polaris Capital Management's SUPN Position: Q1 2026 in Review

Polaris Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 13% in Q1 2026, selling an estimated $168K and leaving 22,500 shares worth $1.16M. The position accounts for 0.1% of the portfolio, ranked #74.

Polaris Capital Management first reported a position in SUPN in Q2 2021 and has held it in 20 quarters since. The position peaked at $1.7M in Q4 2024. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Polaris Capital Management held 22,500 shares of Supernus Pharmaceuticals worth $1.16M as of Q1 2026.
Polaris Capital Management sold 3,300 Supernus Pharmaceuticals shares in Q1 2026, an estimated $168K.
Supernus Pharmaceuticals made up 0.1% of Polaris Capital Management's portfolio in Q1 2026, its #74 holding.
Polaris Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
Polaris Capital Management's Supernus Pharmaceuticals position peaked at $1.7M in Q4 2024.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Polaris Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.